Analysts at William Blair assumed coverage on shares of Neuronetics (NASDAQ:STIM - Get Free Report) in a research report issued on Monday, Briefing.com reports. The brokerage set an "outperform" rating on the stock.
STIM has been the topic of several other research reports. Citigroup restated a "market outperform" rating on shares of Neuronetics in a research report on Tuesday, July 21st. Weiss Ratings reiterated a "sell (e+)" rating on shares of Neuronetics in a research report on Monday, September 14th. B. Riley Financial lifted their price objective on shares of Neuronetics from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Friday, November 6th. Finally, BTIG Research restated a "buy" rating and issued a $6.00 target price on shares of Neuronetics in a report on Thursday, September 17th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.00.
Check Out Our Latest Stock Analysis on Neuronetics
Neuronetics Stock Performance
STIM stock opened at $1.39 on Monday. The company has a debt-to-equity ratio of 2.76, a current ratio of 2.01 and a quick ratio of 1.82. Neuronetics has a 1-year low of $0.80 and a 1-year high of $3.44. The business has a 50 day simple moving average of $2.35 and a two-hundred day simple moving average of $1.87. The company has a market capitalization of $108.04 million, a price-to-earnings ratio of -4.21 and a beta of 1.36.
Neuronetics (NASDAQ:STIM - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.07. The business had revenue of $41.96 million for the quarter, compared to analysts' expectations of $40.42 million. Neuronetics had a negative net margin of 14.45% and a negative return on equity of 102.23%. Research analysts anticipate that Neuronetics will post -0.30 EPS for the current fiscal year.
Insider Buying and Selling at Neuronetics
In other news, major shareholder Jorey Chernett sold 2,187,051 shares of the company's stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $1.15, for a total value of $2,515,108.65. Following the completion of the sale, the insider owned 7,325,577 shares of the company's stock, valued at approximately $8,424,413.55. This represents a 22.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 3,335,411 shares of company stock valued at $4,479,146. 8.40% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Neuronetics
A number of hedge funds and other institutional investors have recently bought and sold shares of STIM. Madryn Asset Management LP purchased a new stake in Neuronetics during the 2nd quarter valued at about $24,102,634. Marshall Wace LLP increased its holdings in shares of Neuronetics by 219.5% in the third quarter. Marshall Wace LLP now owns 1,551,840 shares of the company's stock valued at $3,631,000 after purchasing an additional 1,066,148 shares during the period. FourWorld Capital Management LLC raised its stake in shares of Neuronetics by 59.9% in the first quarter. FourWorld Capital Management LLC now owns 1,489,322 shares of the company's stock worth $2,160,000 after purchasing an additional 558,072 shares during the last quarter. HighTower Advisors LLC raised its stake in shares of Neuronetics by 95.4% in the third quarter. HighTower Advisors LLC now owns 1,101,502 shares of the company's stock worth $2,578,000 after purchasing an additional 537,761 shares during the last quarter. Finally, BlackRock Inc. purchased a new position in shares of Neuronetics in the second quarter worth about $776,000. Hedge funds and other institutional investors own 53.59% of the company's stock.
About Neuronetics
(
Get Free Report)
Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain. NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Neuronetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neuronetics wasn't on the list.
While Neuronetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.